Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

SEED Therapeutics Announces Poster Presentation at AACR Annual Meeting 2026

globenewswire.com
EL Eli Lilly and Co. is mentioned as a cornerstone investor and research collaborator for SEED Therapeutics, indicating a supportive but not directly impactful relationship based on this article alone.

SEED Therapeutics Announces Poster Presentation at AACR Annual Meeting 2026 KING OF PRUSSIA, Pa., March 30, 2026 (GLOBE NEWSWIRE) -- SEED Therapeutics, Inc. (“SEED”), a clinical-stage biotechnology company specializing in molecular glue degraders, today announced that it will have a poster presentation at the 2026 Annual Meeting of the American Association for Cancer Research ("AACR"), taking place on April 17 through 22, 2026 in San Diego, California.

Presentation Details:

About SEED Therapeutics

SEED Therapeutics is a clinical-stage biotechnology company pioneering rationally designed molecular glue degraders to treat diseases driven by undruggable proteins. Its proprietary RITE3™ platform enables targeted protein degradation with small-molecule precision.

SEED Therapeutics was co-founded by four scientific leaders:

Eli Lilly and Co. and Eisai Co., Ltd., are cornerstone investors and research collaborators, supporting SEED’s mission to unlock undruggable disease targets. The company’s pipeline includes six molecular glue programs across oncology, neurodegeneration, immunology, and virology.

Media & Investor Contact

IR@seedtherapeutics.com

PR@seedtherapeutics.com

www.seedtherapeutics.com